TRICARE Prior Authorization Request Form for ozanimod **(Zeposia)**

JOHNS HOPKINS
HEALTH PLANS
7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior Authorization does not expire.

Step 1 **Please complete patient and physician information** (please print):

Patient Name: _____ Physician Name: _____
Address: _____ Address: _____
_____ _____
Sponsor ID # _____ Phone #: _____
Date of Birth: Secure Fax #:

Step 2 **Please complete the clinical assessment:**

1. What is the indication or diagnosis?	☐ Relapsing forms of multiple sclerosis (MS) - Proceed to question **2** ☐ Moderate to severe active Ulcerative Colitis - Proceed to question **5** ☐ Other – **STOP Coverage not approved**	
2. Is the requested medication prescribed by a neurologist?	☐ Yes Proceed to question **3**	☐ No **STOP** **Coverage not approved**
3. Is the patient concurrently using a disease-modifying therapy (for example, beta interferons [Avonex, Betaseron, Rebif, Plegridy, Extavia], glatiramer [Copaxone, Glatopa], dimethyl fumarate [Tecfidera], diroximel fumarate [Vumerity], monomethyl fumarate [Bafiertam], cladribine [Mavenclad], teriflunamide [Aubagio])?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **4**
4. Has the patient failed a course of another S1p receptor modulator (such as, Gilenya, Mayzent)?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **16**
5. Is the patient greater than or equal to 18 year(s) of age?	☐ Yes Proceed to question **6**	☐ No **STOP** **Coverage not approved**

TRICARE Prior Authorization Request Form for ozanimod **(Zeposia)**

6. Humira is the Department of Defense's preferred targeted immunomodulatory biologic agent for ulcerative colitis. Has the patient tried Humira?	☐ Yes Proceed to question **7**	☐ No Proceed to question **9**
7. Has the patient had an inadequate response to Humira?	☐ Yes Proceed to question **10**	☐ No Proceed to question **8**
8. Has the patient experienced an adverse reaction to Humira that is not expected to occur with Zeposia?	☐ Yes Proceed to question **10**	☐ No **STOP** **Coverage not approved**
9. Does the patient have a contraindication to Humira?	☐ Yes Proceed to question **10**	☐ No **STOP** **Coverage not approved**
10. Has the patient tried Velsipity?	☐ Yes Proceed to question **11**	☐ No Proceed to question **13**
11. Has the patient had an inadequate response to Velsipity?	☐ Yes Proceed to question **14**	☐ No Proceed to question **12**
12. Has the patient experienced an adverse reaction to Velsipity that is not expected to occur with Zeposia?	☐ Yes Proceed to question **14**	☐ No **STOP** **Coverage not approved**
13. Does the patient have a contraindication to Velsipity?	☐ Yes Proceed to question **14**	☐ No **STOP** **Coverage not approved**
14. Is the patient receiving oral immunomodulatory or biologic therapies concomitantly?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **15**
15. Has the patient had an inadequate response to non-biologic systemic therapy? (For example - methotrexate, aminosalicylates [for example, sulfasalazine, mesalamine], corticosteroids, immunosuppressants [such as, azathioprine], etc.)	☐ Yes Proceed to question **16**	☐ No **STOP** **Coverage not approved**

TRICARE Prior Authorization Request Form for ozanimod **(Zeposia)**

16. Does the provider acknowledge that all recommended Zeposia monitoring has been completed and the patient will be monitored throughout treatment as recommended in the label? Monitoring includes the following: • **complete blood count (CBC),** • **liver function tests (LFT),** • **varicella zoster virus (VZV) antibody serology,** • **electrocardiogram (ECG), and** • **macular edema screening as indicated**	☐ Yes Proceed to question **17**	☐ No **STOP** **Coverage not approved**
17. Is the patient of childbearing potential?	☐ Yes Proceed to question **18**	☐ No Proceed to question **19**
18. Will the patients of childbearing potential agree to use effective contraception during treatment and for 3 months after stopping therapy?	☐ Yes Proceed to question **19**	☐ No **STOP** **Coverage not approved**
19. Will the requested medication be used in patients with significant cardiac history, including: • **Patients with a recent history (within the past 6 months) of class III/IV heart failure, myocardial infarction, unstable angina, stroke, transient ischemic attack, or decompensated heart failure requiring hospitalization** • **Patients with a history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome, unless they have a functioning pacemaker?**	☐ Yes **STOP** **Coverage not approved**	☐ No **Sign and date below**

Step 3 **I certify the above is true to the best of my knowledge.**
Please sign and date:

_____ _____
Prescriber Signature Date

[26 June 2024]

For Internal Use Only	
☐ Approved:	Duration of Approval: _____month(s)
☐ Denied:	Authorized By:
☐ Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: